211 related articles for article (PubMed ID: 25501904)
1. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.
Di Lisi D; Leggio G; Vitale G; Arrotti S; Iacona R; Inciardi RM; Nobile D; Bonura F; Novo G; Russo A; Novo S
J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):270-5. PubMed ID: 25501904
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced cardiotoxicity: role of the conventional echocardiography and the tissue Doppler.
Di Lisi D; Bonura F; Macaione F; Cuttitta F; Peritore A; Meschisi M; Novo G; D'Alessandro N; Novo S
Minerva Cardioangiol; 2011 Aug; 59(4):301-8. PubMed ID: 21705993
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction.
Di Lisi D; Bonura F; Macaione F; Peritore A; Meschisi M; Cuttitta F; Novo G; D'Alessandro N; Novo S
Anticancer Drugs; 2011 Jun; 22(5):468-72. PubMed ID: 21301318
[TBL] [Abstract][Full Text] [Related]
4. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
6. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
Levis BE; Binkley PF; Shapiro CL
Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
9. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
10. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
[TBL] [Abstract][Full Text] [Related]
11. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
[TBL] [Abstract][Full Text] [Related]
12. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
Nagy AC; Tolnay E; Nagykálnai T; Forster T
Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
[TBL] [Abstract][Full Text] [Related]
14. Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy.
Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Loperfido F; Biondi-Zoccai G
Minerva Cardioangiol; 2007 Dec; 55(6):711-20. PubMed ID: 18091640
[TBL] [Abstract][Full Text] [Related]
15. Potential usefulness of diastolic parameters measured by strain imaging echocardiography in the early prediction of chemotherapy-induced cardiotoxicity.
Hernandez-Suarez DF; López-Candales A
Med Hypotheses; 2017 Apr; 101():30-32. PubMed ID: 28351486
[TBL] [Abstract][Full Text] [Related]
16. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
[TBL] [Abstract][Full Text] [Related]
17. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
Radulescu D; Buzdugan E; Ciuleanu TE; Todor N; Stoicescu L
J BUON; 2013; 18(4):1052-7. PubMed ID: 24344038
[TBL] [Abstract][Full Text] [Related]
18. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
19. Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer.
Lotrionte M; Cavarretta E; Abbate A; Mezzaroma E; De Marco E; Di Persio S; Loperfido F; Biondi-Zoccai G; Frati G; Palazzoni G
Am J Cardiol; 2013 Oct; 112(7):1005-12. PubMed ID: 23768465
[TBL] [Abstract][Full Text] [Related]
20. Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients.
Dores H; Abecasis J; Correia MJ; Gândara F; Fonseca C; Azevedo J; Arroja I; Martins A; Mendes M
Arq Bras Cardiol; 2013 Apr; 100(4):328-32. PubMed ID: 23525273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
